Comparative Pharmacology
Head-to-head clinical analysis: DICLOFENAC versus NAPRELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOFENAC versus NAPRELAN.
DICLOFENAC vs NAPRELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.
750 mg to 1000 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life ~2 h (diclofenac immediate-release); enterohepatic recirculation may produce secondary peaks. Clinical context: Short half-life requires multiple daily dosing for sustained effect.
Clinical Note
moderateDiclofenac + Gatifloxacin
"Diclofenac may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiclofenac + Rosoxacin
"Diclofenac may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiclofenac + Levofloxacin
"Diclofenac may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiclofenac + Trovafloxacin
"Diclofenac may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life: 10-20 hours; context: allows twice-daily or once-daily dosing for chronic pain or inflammation.
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Renal: 50-60% as metabolites and conjugates; biliary/fecal: ~5%; remainder uncharacterized.
Category D/X
Category C
NSAID
NSAID